Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2015-07-23 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about hosting a second quarter 2015 financial results conference call. The document is short (2287 characters) and primarily serves as an announcement of the conference call rather than containing the actual financial results or detailed financial data. It does not contain substantive financial statements or analysis itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Interim Report. Therefore, the appropriate classification is RNS with high confidence.
2015-07-23 English
FORM 6-K FILING DOCUMENT
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about the closing of a public offering of American Depository Shares. The document is short (2285 characters) and primarily serves as an announcement of a financing event rather than a detailed financial report. It does not contain comprehensive financial statements or detailed analysis but rather an update on a capital raising activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2015-07-22 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes exhibits such as an Underwriting Agreement and legal opinions, indicating it relates to financing or capital raising activities. The document length is 2407 characters, which is relatively short and primarily serves as a regulatory filing to disclose material information between annual reports. Form 6-K filings are typically considered Regulatory Filings (RNS) as they provide updates and disclosures but are not full financial reports or earnings releases. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-07-21 English
FORM 424(B)(5)
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of American Depositary Shares (ADSs) by RedHill Biopharma Ltd. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and other offering-related disclosures. This type of filing is a capital raising document that updates and supplements a previously filed prospectus. It is not an annual or quarterly report, earnings release, management discussion, or any other type of financial report. It is specifically a capital/financing update related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence in this classification.
2015-07-17 English
FORM 6-K FILING DOCUMENT
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about pricing a public offering of American Depository Shares. The document is short (2272 characters) and primarily serves as an announcement of a financing event rather than a detailed financial report. It does not contain comprehensive financial statements or detailed analysis. According to the definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Therefore, this document is best classified as a Capital/Financing Update (CAP).
2015-07-17 English
FORM FWP
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the size of a proposed public offering of American Depository Shares by RedHill Biopharma. It references a shelf registration statement and prospectus filed with the SEC, but does not contain financial statements or detailed financial analysis. The document is primarily an announcement of a capital raising activity, specifically a public offering of shares. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 8262 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or prospectus itself.
2015-07-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.